Related Experiment Video

Updated: May 13, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

[New treatments for castration-resistant prostate cancer]

B Sautois1, C Gennigens

  • 1Service d'Oncologie Médicale, CHU de Liège, Belgique. brieuc.sautois@chu.ulg.ac.be

Revue Medicale De Liege
|March 9, 2013
PubMed

Insights

New chemotherapy options like cabazitaxel, abiraterone, and enzalutamide improve survival for men with castration-resistant prostate cancer after docetaxel treatment.

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Docetaxel chemotherapy is standard for symptomatic castration-resistant prostate cancer.
  • Docetaxel resistance is common, necessitating effective second-line treatments.
  • Historically, mitoxantrone was a common but suboptimal choice for resistant disease.

Purpose of the Study:

  • To review new therapeutic options for metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel therapy.
  • To highlight recent advancements in second-line treatment for prostate cancer.

Main Methods:

  • Analysis of randomized phase 3 multicenter clinical trials published since 2010.
  • Review of data on cabazitaxel, abiraterone, and enzalutamide efficacy.

Main Results:

  • Cabazitaxel, abiraterone, and enzalutamide demonstrated improved overall survival in mCRPC patients previously treated with chemotherapy.
  • These modest survival benefits were considered clinically significant.

Conclusions:

  • New agents offer improved outcomes for patients with docetaxel-resistant castration-resistant prostate cancer.
  • Reimbursement of cabazitaxel and abiraterone in Belgium in 2012 reflects their clinical significance.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Murine Prostate Micro-dissection and Surgical Castration08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...